Abstract
Background: Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo. Methods: A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups. Results: A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m2 (0.007 mL/s/1.73 m2; P = 0.28) during a follow-up period of more than 8 years. Conclusion: Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 812-819 |
| Number of pages | 8 |
| Journal | American Journal of Kidney Diseases |
| Volume | 46 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2005 |
| Externally published | Yes |
Fingerprint
Keywords
- Hypercholesterolemia
- Randomized controlled trial
- Renal function
ASJC Scopus subject areas
- Nephrology
Cite this
The effect of cholesterol reduction with cholestyramine on renal function. / Kshirsagar, Abhijit V.; Shoham, David A.; Bang, Heejung; Hogan, Susan L.; Simpson, Ross J.; Colindres, Romulo E.
In: American Journal of Kidney Diseases, Vol. 46, No. 5, 11.2005, p. 812-819.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect of cholesterol reduction with cholestyramine on renal function
AU - Kshirsagar, Abhijit V.
AU - Shoham, David A.
AU - Bang, Heejung
AU - Hogan, Susan L.
AU - Simpson, Ross J.
AU - Colindres, Romulo E.
PY - 2005/11
Y1 - 2005/11
N2 - Background: Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo. Methods: A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups. Results: A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m2 (0.007 mL/s/1.73 m2; P = 0.28) during a follow-up period of more than 8 years. Conclusion: Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.
AB - Background: Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo. Methods: A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups. Results: A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m2 (0.007 mL/s/1.73 m2; P = 0.28) during a follow-up period of more than 8 years. Conclusion: Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.
KW - Hypercholesterolemia
KW - Randomized controlled trial
KW - Renal function
UR - http://www.scopus.com/inward/record.url?scp=27144474760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27144474760&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2005.08.012
DO - 10.1053/j.ajkd.2005.08.012
M3 - Article
C2 - 16253720
AN - SCOPUS:27144474760
VL - 46
SP - 812
EP - 819
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
SN - 0272-6386
IS - 5
ER -